Hillevax
Ozzie Berger's work experience begins in 1995 at Merck, where they worked as a Regulatory Coordinator until 2001. From 2002 to 2009, Ozzie held various roles at GSK, including Director and Lead of US Regulatory Affairs, Vaccines. They then became the Global Regulatory Leader for Adjuvant Strategy from 2012 to 2013, followed by the Head of Platform Technologies in Global Regulatory Affairs for Vaccines from 2014 to 2015. After that, Ozzie served as the Vice President and RA Head of the R&D Center in the USA at GSK from 2015 to 2022. Ozzie's most recent position is as a Senior Vice President at HilleVax, starting in November 2022.
Ozzie Berger has attended Arcadia University, although the specific duration and degree information are not provided.
This person is not in any offices
Hillevax
2 followers
HilleVax is a biopharmaceutical company focused on the development and commercialization of novel vaccines. Their initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.